Home
Letmo Research
We provide scientific due diligence and in-depth investment research, with particular strength in biotechnology, biomedicine, gene therapy and genomics. What we do best is judging whether a technology or a business model can actually work, and finding the plans that cannot, including the ones built to mislead. We write research to order and publish reports on this site: some are public, the rest are open to members. When the opportunity is right, we also invest our own capital. We choose to make as much of our work public as we can, so it can be reviewed, challenged and improved over time (all 1,319 trades and 424 deposits and withdrawals since 2017 are public).
- Portfolio
- SPY
Drag across the chart to focus on a period; click to pin a month
- Cumulative Return
- 505.72%SPY: 230.07%
- Annualized Return
- 21.76%SPY: 13.94%
- Months Ahead of SPY
- 60.36%67 of 111 months
- Date
- 2017-09-25 to 2026-11-19
Latest Paid In-Depth Research
View all paid in-depth researchLast updated ONT - Oxford Nanopore
The Nanopore That Can Sequence Anything Now Has to Pick a Few Things
Last updated TXG - 10x Genomics
The Single-Cell Standard, Priced in Advance for Atera
Last updated PACB - Pacific Biosciences
Long Reads Won the Technology, Not Yet the Business
Last updated BNGO - Bionano Genomics
A Real Technology Whose Window Sequencing Is Slowly Closing
Latest Free Core Research
View all research reportsLast updated QBTS - D-Wave Quantum
Quantum Computing Will Not Replace Classical Computing
Last updated TMC - The Metals Company
The Core Problem with Deep-Sea Mining Is Not the Permit, but Technology and Commercial Cost
Last updated ASST - Strive
The Leveraged Bitcoin Business Model Is Worth Nothing, The Premium Has To Compress
Last updated SPCX - SpaceX
The Space Data Center Is a Story Told Without Sincerity
Last updated TSLA - Tesla